http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014121334-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N2005-1098 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 2012-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014121334-A |
| titleOfInvention | COMPOUNDS 5- (PYRIDIN-2-ILAMINO) -PYRAZIN-2-CARBONITRIL AND THEIR THERAPEUTIC USE |
| abstract | 1. A compound of the following formula or a pharmaceutically acceptable salt, hydrate or solvate thereof: wherein: —R independently is: each — R independently is —H or saturated aliphatic C 1-6 alkyl; —R independently is —NHR, —NR or —OR; each is —R independently represents a saturated aliphatic C1-6alkyl; -R independently represents -R, -R, -R, -R, -R or -R; -R represents independently: -R represents a saturated aliphatic C1-6 alkyl; -R represents -CF; -R independently represents - F, -O, -Br or -I; -R is -C≡CH, -C≡C-R or -C≡CR-OH; -R is a saturated aliphatic C1-6 alkyl; -R is a saturated aliphatic C1-6 alkylene; -R is independently saturated Cycloalkyl; -R is -C (= O) OR; i-R is a saturated aliphatic C1-6alkyl. 2. A compound according to claim 1, characterized in that -R is: 3. Connection under item 1, characterized in that -R represents: 4. A compound according to claim 1, characterized in that —R is —H or —Me. 5. A compound according to claim 2, characterized in that -R is -Me. 6. A compound according to claim 3, characterized in that —R is —H or —Me. 7. A compound according to claim 4, characterized in that —R independently represents —NHR or —NR, wherein each —R independently represents — Me or —Et. 8. A compound according to claim 5, characterized in that —R independently represents —NHR or —NR, wherein each —R independently represents — Me or —Et. 9. A compound according to claim 6, characterized in that —R independently represents —NHR or —NR, wherein each —R independently represents — Me or —Et.10. The compound according to claim 4, characterized in that -R is |
| priorityDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467991391 |
Total number of triples: 19.